A Phase 2/3 clinical trial is again recruiting participants to continue investigating the immunomodulator Leukine (sargramostim) in combination with checkpoint inhibitors Yervoy (ipilimumab) and Opdivo (nivolumab) as an initial treatment for patients with melanoma. The decision to resume enrollment follows positive — but as yet, undisclosed — safety and survival results from the first 250 … Continue reading Enrollment Underway in Melanoma Trial Testing Leukine Triple Combo